Contributor Disclosures for Mucopolysaccharidosis Type IV

Role Name Disclosure Details Author  Nancy Braverman, MD, Assistant Professor, McKusick-Nathans Institute of Genetic Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine none Details Coauthor  Julie Hoover-Fong, MD, Assistant Professor, Clinical Director, Greenberg Center for Skeletal Dysplasias, McKusick-Nathans Institute of Genetic Medicine, Department of Pediatrics, Johns Hopkins Medical Center Nothing to disclose Details Coauthor  Michael C Ain, MD, Assistant Professor, Departments of Neurosurgery and General Surgery, Division of Pediatric Orthopedic Surgery, Johns Hopkins University School of Medicine Nothing to disclose Details Medical Editor  Karl S Roth, MD, Professor and Chair, Department of Pediatrics, Creighton University School of Medicine Nothing to disclose Details Pharmacy Editor  Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc Pfizer Inc Avanir Pharma Details Managing Editor  Margaret McGovern, MD, PhD, Vice Chair, Professor, Department of Human Genetics, Mount Sinai School of Medicine Nothing to disclose Details CME Editor  Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine Baxter Pfizer Details Chief Editor  Bruce Buehler, MD, Professor, Department of Pediatrics, Pathology and Microbiology, Executive Director, Hattie B Munroe Center for Human Genetics and Rehabilitation, University of Nebraska Medical Center Nothing to disclose Details CONTRIBUTOR DISCLOSURE FORM Contributor Name: Nancy Braverman  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** none None None   Off label or investigational use of medication none Contributor Disclosure Contributor: Contributor Disclosure: Julie Hoover-Fong, Coauthor  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Michael C Ain, Coauthor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Karl S Roth  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Mary L Windle  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Pfizer Inc Stock Investment from broker recommendation   Avanir Pharma Stock Investment from broker recommendation   Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: Margaret McGovern, Managing Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Daniel Rauch  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Baxter Honoraria Consulting   Pfizer Honoraria Consulting   Off label or investigational use of medication none CONTRIBUTOR DISCLOSURE FORM Contributor Name: Bruce Buehler  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication